Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Predictors of tuberculosis knowledge, attitudes and practices in urban slums in Nigeria: a cross-sectional study.

Balogun MR, Sekoni AO, Meloni ST, Odukoya OO, Onajole AT, Longe-Peters OA, Ogunsola FT, Kanki PJ.

Pan Afr Med J. 2019 Feb 4;32:60. doi: 10.11604/pamj.2019.32.60.14622. eCollection 2019.

2.

Safety and efficacy of rifabutin among HIV/TB-coinfected children on lopinavir/ritonavir-based ART.

Rawizza HE, Darin KM, Oladokun R, Brown B, Ogunbosi B, David N, Akanmu S, Olaitan O, Chang C, Scarsi KK, Okonkwo P, Kanki PJ.

J Antimicrob Chemother. 2019 May 28. pii: dkz219. doi: 10.1093/jac/dkz219. [Epub ahead of print]

PMID:
31139825
3.

Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults.

Agbaji OO, Abah IO, Ebonyi AO, Gimba ZM, Abene EE, Gomerep SS, Falang KD, Anejo-Okopi J, Agaba PA, Ugoagwu PO, Agaba EI, Imade GE, Sagay AS, Okonkwo P, Idoko JA, Kanki PJ.

J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958218821963. doi: 10.1177/2325958218821963.

4.

Effects of selenium supplementation on pregnancy outcome and disease progression in HIV-infected pregnant women in Lagos, Nigeria: Study protocol for a randomised, double-blind, placebo-controlled trial.

Okunade KS, John-Olabode S, Akinsola OJ, Akinajo O, Akanmu SA, Kanki PJ.

Medicine (Baltimore). 2019 Jan;98(3):e12735. doi: 10.1097/MD.0000000000012735.

5.

Erratum for Herrera et al., "T Cell Responses to Nonstructural Protein 3 Distinguish Infections by Dengue and Zika Viruses".

Herrera BB, Tsai WY, Brites C, Luz E, Pedroso C, Drexler JF, Wang WK, Kanki PJ.

MBio. 2018 Oct 23;9(5). pii: e01995-18. doi: 10.1128/mBio.01995-18. No abstract available.

6.

T Cell Responses to Nonstructural Protein 3 Distinguish Infections by Dengue and Zika Viruses.

Herrera BB, Tsai WY, Brites C, Luz E, Pedroso C, Drexler JF, Wang WK, Kanki PJ.

MBio. 2018 Aug 7;9(4). pii: e00755-18. doi: 10.1128/mBio.00755-18. Erratum in: MBio. 2018 Oct 23;9(5):.

7.

A modified anthrax toxin-based enzyme-linked immunospot assay reveals robust T cell responses in symptomatic and asymptomatic Ebola virus exposed individuals.

Herrera BB, Hamel DJ, Oshun P, Akinsola R, Akanmu AS, Chang CA, Eromon P, Folarin O, Adeyemi KT, Happi CT, Lu Y, Ogunsola F, Kanki PJ.

PLoS Negl Trop Dis. 2018 May 24;12(5):e0006530. doi: 10.1371/journal.pntd.0006530. eCollection 2018 May.

8.

Retention in Differentiated Care: Multiple Measures Analysis for a Decentralized HIV Care and Treatment Program in North Central Nigeria.

Agaba PA, Genberg BL, Sagay AS, Agbaji OO, Meloni ST, Dadem NY, Kolawole GO, Okonkwo P, Kanki PJ, Ware NC.

J AIDS Clin Res. 2018;9(2). pii: 756. doi: 10.4172/2155-6113.1000756. Epub 2018 Feb 13.

9.

Treatment Outcomes Among Older Human Immunodeficiency Virus-Infected Adults in Nigeria.

Agaba PA, Meloni ST, Sule HM, Agbaji OO, Sagay AS, Okonkwo P, Idoko JA, Kanki PJ.

Open Forum Infect Dis. 2017 Feb 12;4(2):ofx031. doi: 10.1093/ofid/ofx031. eCollection 2017 Spring.

10.

Sustained Specific and Cross-Reactive T Cell Responses to Zika and Dengue Virus NS3 in West Africa.

Herrera BB, Tsai WY, Chang CA, Hamel DJ, Wang WK, Lu Y, Mboup S, Kanki PJ.

J Virol. 2018 Mar 14;92(7). pii: e01992-17. doi: 10.1128/JVI.01992-17. Print 2018 Apr 1.

11.

Implication of First-Line Antiretroviral Therapy Choice on Second-Line Options.

Meloni ST, Onwuamah CK, Agbaji O, Chaplin B, Olaleye DO, Audu R, Samuels J, Ezechi O, Imade G, Musa AZ, Odaibo G, Okpokwu J, Rawizza H, Mu'azu MA, Dalhatu I, Ahmed M, Okonkwo P, Raizes E, Ujah IAO, Yang C, Idigbe EO, Kanki PJ.

Open Forum Infect Dis. 2017 Nov 2;4(4):ofx233. doi: 10.1093/ofid/ofx233. eCollection 2017 Fall.

12.

Distinct Pattern of Thymidine Analogue Mutations with K65R in Patients Failing Tenofovir-Based Antiretroviral Therapy.

Chaplin B, Imade G, Onwuamah C, Odaibo G, Audu R, Okpokwu J, Olaleye D, Meloni S, Rawizza H, Muazu M, Musa AZ, Samuel J, Agbaji O, Ezechi O, Idigbe E, Kanki PJ.

AIDS Res Hum Retroviruses. 2018 Feb;34(2):228-233. doi: 10.1089/AID.2017.0198. Epub 2017 Nov 30.

PMID:
29084434
13.

Drug resistance patterns following pharmacy stock shortage in Nigerian Antiretroviral Treatment Program.

Meloni ST, Chaplin B, Idoko J, Agbaji O, Akanmu S, Imade G, Okonkwo P, Murphy RL, Kanki PJ.

AIDS Res Ther. 2017 Oct 13;14(1):58. doi: 10.1186/s12981-017-0184-5.

14.

Prevalence and predictors of severe menopause symptoms among HIV-positive and -negative Nigerian women.

Agaba PA, Meloni ST, Sule HM, Ocheke AN, Agaba EI, Idoko JA, Kanki PJ.

Int J STD AIDS. 2017 Nov;28(13):1325-1334. doi: 10.1177/0956462417704778. Epub 2017 Apr 14.

PMID:
28409538
15.

Continued Transmission of Zika Virus in Humans in West Africa, 1992-2016.

Herrera BB, Chang CA, Hamel DJ, Mboup S, Ndiaye D, Imade G, Okpokwu J, Agbaji O, Bei AK, Kanki PJ.

J Infect Dis. 2017 May 15;215(10):1546-1550. doi: 10.1093/infdis/jix182.

16.

Sexual dysfunction and its determinants among women infected with HIV.

Agaba PA, Meloni ST, Sule HM, Agaba EI, Idoko JA, Kanki PJ.

Int J Gynaecol Obstet. 2017 Jun;137(3):301-308. doi: 10.1002/ijgo.12140. Epub 2017 Mar 22.

PMID:
28273350
17.

Mortality among pulmonary tuberculosis and HIV-1 co-infected Nigerian children being treated for pulmonary tuberculosis and on antiretroviral therapy: a retrospective cohort study.

Ebonyi AO, Oguche S, Agbaji OO, Sagay AS, Okonkwo PI, Idoko JA, Kanki PJ.

Germs. 2016 Dec 2;6(4):139-150. doi: 10.11599/germs.2016.1099. eCollection 2016 Dec.

18.

Long-Term Outcomes on Antiretroviral Therapy in a Large Scale-Up Program in Nigeria.

Meloni ST, Chang CA, Eisen G, Jolayemi T, Banigbe B, Okonkwo PI, Kanki PJ.

PLoS One. 2016 Oct 20;11(10):e0164030. doi: 10.1371/journal.pone.0164030. eCollection 2016.

19.

Prevalence of and risk factors for pulmonary tuberculosis among newly diagnosed HIV-1 infected Nigerian children.

Ebonyi AO, Oguche S, Ejeliogu EU, Agbaji OO, Shehu NY, Abah IO, Sagay AS, Ugoagwu PO, Okonkwo PI, Idoko JA, Kanki PJ.

Germs. 2016 Mar 1;6(1):21-8. doi: 10.11599/germs.2016.1085. eCollection 2016 Mar.

20.

Building laboratory capacity to support HIV care in Nigeria: Harvard/APIN PEPFAR, 2004-2012.

Hamel DJ, Sankalé JL, Samuels JO, Sarr AD, Chaplin B, Ofuche E, Meloni ST, Okonkwo P, Kanki PJ.

Afr J Lab Med. 2015;4(1). pii: 190. Epub 2015 May 14.

21.

Tuberculosis Incidence and Risk Factors Among Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy in a Large HIV Program in Nigeria.

Chang CA, Meloni ST, Eisen G, Chaplin B, Akande P, Okonkwo P, Rawizza HE, Tchetgen Tchetgen E, Kanki PJ.

Open Forum Infect Dis. 2015 Oct 17;2(4):ofv154. doi: 10.1093/ofid/ofv154. eCollection 2015 Dec.

22.

Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort.

Scarsi KK, Eisen G, Darin KM, Meloni ST, Rawizza HE, Tchetgen Tchetgen EJ, Agbaji OO, Onwujekwe DI, Gashau W, Nkado R, Okonkwo P, Murphy RL, Kanki PJ; Harvard/APIN PEPFAR Team.

Clin Infect Dis. 2016 Feb 15;62(4):512-8. doi: 10.1093/cid/civ928. Epub 2015 Nov 10.

23.

Incidence and predictors of adverse drug events in an African cohort of HIV-infected adults treated with efavirenz.

Abah IO, Akanbi M, Abah ME, Finangwai AI, Dady CW, Falang KD, Ebonyi AO, Okopi JA, Agbaji OO, Sagay AS, Okonkwo P, Idoko JA, Kanki PJ.

Germs. 2015 Sep 1;5(3):83-91. doi: 10.11599/germs.2015.1075. eCollection 2015 Sep.

24.

Patterns of Adherence and Loss to Follow-Up in Pediatric Patients on ART in Nigeria.

Meloni ST, Chaplin B, Chang C, Rawizza H, Okonkwo P, Kanki PJ.

Curr HIV Res. 2015;13(3):210-8.

PMID:
25986372
25.

Loss to Follow-Up within the Prevention of Mother-to-Child Transmission Care Cascade in a Large ART Program in Nigeria.

Rawizza HE, Chang CA, Chaplin B, Ahmed IA, Meloni ST, Oyebode T, Banigbe B, Sagay AS, Adewole IF, Okonkwo P, Kanki PJ; APIN PEPFAR Team.

Curr HIV Res. 2015;13(3):201-9.

26.

Mother-to-Child Transmission Outcomes of HIV-Exposed Infants Followed Up in Jos North-Central Nigeria.

Sagay AS, Ebonyi AO, Meloni ST, Musa J, Oguche S, Ekwempu CC, Oyebode T, Ejeliogu E, Imade GE, Agbaji OO, Okonkwo P, Kanki PJ.

Curr HIV Res. 2015;13(3):193-200.

PMID:
25986370
27.

Treatment Discontinuation in Adult HIV-Infected Patients on First-Line Antiretroviral Therapy in Nigeria.

Agbaji OO, Abah IO, Falang KD, Ebonyi AO, Musa J, Ugoagwu P, Agaba PA, Sagay AS, Jolayemi T, Okonkwo P, Idoko JA, Kanki PJ.

Curr HIV Res. 2015;13(3):184-92.

PMID:
25986369
28.

Immunological and Virological Outcomes of Patients Switched from LPV/r to ATV/r-Containing Second- Line Regimens.

Akanmu AS, Adeyemo T, Lesi F, Bello FO, Okwuegbuna K, Oloko K, Awolola A, Ogunsola FT, Okonkwo P, Kanki PJ.

Curr HIV Res. 2015;13(3):176-83.

PMID:
25986368
29.

Editorial: Programmatic Evaluation of HIV Prevention and Treatment in Nigeria.

Kanki PJ.

Curr HIV Res. 2015;13(3):174-5. No abstract available.

PMID:
25986367
30.

Trained community volunteers improve tuberculosis knowledge and attitudes among adults in a periurban community in southwest Nigeria.

Balogun M, Sekoni A, Meloni ST, Odukoya O, Onajole A, Longe-Peters O, Ogunsola F, Kanki PJ.

Am J Trop Med Hyg. 2015 Mar;92(3):625-32. doi: 10.4269/ajtmh.14-0527. Epub 2014 Dec 15.

31.

High-risk human papilloma virus and cervical abnormalities in HIV-infected women with normal cervical cytology.

Musa J, Achenbach C, Taiwo B, Berzins B, Silas O, Daru PH, Agbaji O, Imade G, Sagay AS, Idoko JA, Kanki PJ, Murphy RL.

Infect Agent Cancer. 2014 Nov 3;9(1):36. doi: 10.1186/1750-9378-9-36. eCollection 2014.

32.

Enhancement of health research capacity in Nigeria through north-south and in-country partnerships.

Olaleye DO, Odaibo GN, Carney P, Agbaji O, Sagay AS, Muktar H, Akinyinka OO, Omigbodun AO, Ogunniyi A, Gashau W, Akanmu S, Ogunsola F, Chukwuka C, Okonkwo PI, Meloni ST, Adewole I, Kanki PJ, Murphy RL.

Acad Med. 2014 Aug;89(8 Suppl):S93-7. doi: 10.1097/ACM.0000000000000353.

33.

Treatment outcomes in a decentralized antiretroviral therapy program: a comparison of two levels of care in north central Nigeria.

Okonkwo P, Sagay AS, Agaba PA, Yohanna S, Agbaji OO, Imade GE, Banigbe B, Adeola J, Oyebode TA, Idoko JA, Kanki PJ.

AIDS Res Treat. 2014;2014:560623. doi: 10.1155/2014/560623. Epub 2014 Jun 17.

34.

Declining rate of infection with maternal human immunodeficiency virus at delivery units in north-central Nigeria.

Imade GE, Sagay AS, Musa J, Ocheke AN, Adeniyi DS, Idighri M, Powl R, Sendeht A, Ogwuche JP, Elujoba M, Egbodo CO, Oyebode T, Daru PH, Agbaji O, Pam IC, Meloni ST, Okonkwo P, Kanki PJ.

Afr J Reprod Health. 2013 Dec;17(4 Spec No):138-45.

PMID:
24689325
35.

The protective effect of HIV-2 infection: implications for understanding HIV-1 immunity.

Kanki PJ, Rowland-Jones S.

AIDS. 2014 Apr 24;28(7):1065-7. doi: 10.1097/QAD.0000000000000209. No abstract available.

PMID:
24685743
36.

Patients who present late to HIV care and associated risk factors in Nigeria.

Agaba PA, Meloni ST, Sule HM, Agbaji OO, Ekeh PN, Job GC, Nyango N, Ugoagwu PO, Imade GE, Idoko JA, Kanki PJ.

HIV Med. 2014 Aug;15(7):396-405. doi: 10.1111/hiv.12125. Epub 2014 Jan 20.

37.

Predictors of Mortality in a Clinic Cohort of HIV-1 Infected Children Initiated on Antiretroviral Therapy in Jos, Nigeria.

Ebonyi AO, Oguche S, Meloni ST, Sagay SA, Kyriacou DN, Achenbach CJ, Agbaji OO, Oyebode TA, Okonkwo P, Idoko JA, Kanki PJ.

J AIDS Clin Res. 2014;5(12). pii: 403. doi: 10.4172/2155-6113.1000403. Epub 2014 Dec 20.

38.

Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria.

Rawizza HE, Chaplin B, Meloni ST, Darin KM, Olaitan O, Scarsi KK, Onwuamah CK, Audu RA, Chebu PR, Imade GE, Okonkwo P, Kanki PJ.

PLoS One. 2013 Sep 17;8(9):e73582. doi: 10.1371/journal.pone.0073582. eCollection 2013.

39.

Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.

Tang MW, Rhee SY, Bertagnolio S, Ford N, Holmes S, Sigaloff KC, Hamers RL, de Wit TF, Fleury HJ, Kanki PJ, Ruxrungtham K, Hawkins CA, Wallis CL, Stevens W, van Zyl GU, Manosuthi W, Hosseinipour MC, Ngo-Giang-Huong N, Belec L, Peeters M, Aghokeng A, Bunupuradah T, Burda S, Cane P, Cappelli G, Charpentier C, Dagnra AY, Deshpande AK, El-Katib Z, Eshleman SH, Fokam J, Gody JC, Katzenstein D, Koyalta DD, Kumwenda JJ, Lallemant M, Lynen L, Marconi VC, Margot NA, Moussa S, Ndung'u T, Nyambi PN, Orrell C, Schapiro JM, Schuurman R, Sirivichayakul S, Smith D, Zolfo M, Jordan MR, Shafer RW.

J Infect Dis. 2013 Jun 15;207 Suppl 2:S70-7. doi: 10.1093/infdis/jit114.

40.

High-risk human papillomavirus among HIV-infected women with normal cervical cytology: a pilot study in Jos, Nigeria.

Musa J, Taiwo B, Achenbach C, Olugbenga S, Berzins B, Sagay AS, Idoko JA, Kanki PJ, Murphy RL.

Arch Gynecol Obstet. 2013 Dec;288(6):1365-70. doi: 10.1007/s00404-013-2885-x. Epub 2013 May 23.

PMID:
23700253
41.

Sputum smear concentration may misidentify acid-fast bacilli as Mycobacterium tuberculosis in HIV-infected patients.

Dinic L, Idigbe OE, Meloni S, Rawizza H, Akande P, Eisen G, Onwujekwe D, Agbaji O, Ani A, Kanki PJ.

J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):168-77. doi: 10.1097/QAI.0b013e31828983b9.

PMID:
23392466
42.

A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.

Tang MW, Kanki PJ, Shafer RW.

Clin Infect Dis. 2012 Mar;54(6):862-75. doi: 10.1093/cid/cir1034. Review.

43.

Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings.

Rawizza HE, Chaplin B, Meloni ST, Eisen G, Rao T, Sankalé JL, Dieng-Sarr A, Agbaji O, Onwujekwe DI, Gashau W, Nkado R, Ekong E, Okonkwo P, Murphy RL, Kanki PJ; APIN PEPFAR Team.

Clin Infect Dis. 2011 Dec;53(12):1283-90. doi: 10.1093/cid/cir729.

44.

Condom use among antiretroviral therapy patients in Ibadan, Nigeria.

Akinyemi JO, Awolude OA, Adewole IF, Kanki PJ.

J Infect Dev Ctries. 2010 Sep 3;4(8):495-502.

45.

A 5'UTR-spliced mRNA isoform is specialized for enhanced HIV-2 gag translation.

Strong CL, Lanchy JM, Dieng-Sarr A, Kanki PJ, Lodmell JS.

J Mol Biol. 2009 Aug 14;391(2):426-37. doi: 10.1016/j.jmb.2009.06.046. Epub 2009 Jun 23.

46.

The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals.

Ulenga NK, Sarr AD, Hamel D, Sankale JL, Mboup S, Kanki PJ.

AIDS Res Hum Retroviruses. 2008 Oct;24(10):1285-90. doi: 10.1089/aid.2008.0072.

47.

Interplay of reverse transcriptase inhibitor therapy and gag p6 diversity in HIV type 1 subtype G and CRF02_AG.

Ojesina AI, Chaplin B, Sankalé JL, Murphy R, Idigbe E, Adewole I, Ekong E, Idoko J, Kanki PJ.

AIDS Res Hum Retroviruses. 2008 Sep;24(9):1167-74. doi: 10.1089/aid.2007.0308.

48.

Relationship between human immunodeficiency type 1 infection and expression of human APOBEC3G and APOBEC3F.

Ulenga NK, Sarr AD, Thakore-Meloni S, Sankalé JL, Eisen G, Kanki PJ.

J Infect Dis. 2008 Aug 15;198(4):486-92. doi: 10.1086/590212.

PMID:
18598197
49.

Characterization of HIV type 1 reverse transcriptase mutations in infants infected by mothers who received peripartum nevirapine prophylaxis in Jos, Nigeria.

Ojesina AI, Mullins C, Imade G, Samuels J, Sankalé JL, Pam S, Sagay S, Idoko J, Kanki PJ.

AIDS Res Hum Retroviruses. 2007 Dec;23(12):1587-92.

PMID:
18160018
50.

Twenty years of prospective molecular epidemiology in Senegal: changes in HIV diversity.

Hamel DJ, Sankalé JL, Eisen G, Meloni ST, Mullins C, Gueye-Ndiaye A, Mboup S, Kanki PJ.

AIDS Res Hum Retroviruses. 2007 Oct;23(10):1189-96.

PMID:
17961103

Supplemental Content

Loading ...
Support Center